BSE - Delayed Quote INR

Gufic Biosciences Limited (GUFICBIO.BO)

380.55
+0.10
+(0.03%)
At close: May 23 at 3:28:10 PM GMT+5:30
Loading Chart for GUFICBIO.BO
  • Previous Close 380.45
  • Open 378.95
  • Bid 376.70 x --
  • Ask 380.55 x --
  • Day's Range 378.10 - 388.10
  • 52 Week Range 278.00 - 501.10
  • Volume 4,097
  • Avg. Volume 5,788
  • Market Cap (intraday) 38.161B
  • Beta (5Y Monthly) 0.51
  • PE Ratio (TTM) 46.52
  • EPS (TTM) 8.18
  • Earnings Date May 27, 2025 - May 31, 2025
  • Forward Dividend & Yield 0.10 (0.03%)
  • Ex-Dividend Date Sep 18, 2024
  • 1y Target Est --

Gufic Biosciences Limited manufactures and markets active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India, Africa, Asia, Europe, Australia, North America, South America, and internationally. It manufactures APIs and bulk drugs, such as antifungals, anesthetics, immuno suppressants, and intermediates for antifungals. The company also manufactures lyophilized injections, which include antibiotic, antifungal, cardiac medications, infertility treatments, antiviral solutions, and proton pump inhibitors (PPIs) segments. In addition, the company offers criti care, criticare life, ferticare, and spark pharmaceutical products; and herbal, aesthaderm, gufic stridden, and personal care products. It supplies its products to hospital chains and medical facilities. The company was founded in 1970 and is based in Mumbai, India.

www.gufic.com

1,491

Full Time Employees

March 31

Fiscal Year Ends

Recent News: GUFICBIO.BO

View More

Performance Overview: GUFICBIO.BO

Trailing total returns as of 5/23/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .

YTD Return

GUFICBIO.BO
16.54%
S&P BSE SENSEX (^BSESN)
4.58%

1-Year Return

GUFICBIO.BO
10.68%
S&P BSE SENSEX (^BSESN)
8.36%

3-Year Return

GUFICBIO.BO
66.43%
S&P BSE SENSEX (^BSESN)
50.53%

5-Year Return

GUFICBIO.BO
576.12%
S&P BSE SENSEX (^BSESN)
166.43%

Compare To: GUFICBIO.BO

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: GUFICBIO.BO

View More

Valuation Measures

Annual
As of 5/23/2025
  • Market Cap

    38.16B

  • Enterprise Value

    40.92B

  • Trailing P/E

    46.58

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    6.64

  • Enterprise Value/Revenue

    5.29

  • Enterprise Value/EBITDA

    28.06

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    10.12%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    8.1B

  • Net Income Avi to Common (ttm)

    819.76M

  • Diluted EPS (ttm)

    8.18

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    193.96M

  • Total Debt/Equity (mrq)

    51.54%

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: GUFICBIO.BO

View More

Company Insights: GUFICBIO.BO

Research Reports: GUFICBIO.BO

View More

People Also Watch